Recruiting × OTHER × Lymphoma, B-Cell, Marginal Zone × Clear all CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Phase 1 Recruiting
24 enrolled
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
Phase 2 Recruiting
33 enrolled
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Phase NA Recruiting
200 enrolled
Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
Phase 2 Recruiting
50 enrolled
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Phase 2 Recruiting
60 enrolled
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
Recruiting
100 enrolled
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Phase 1/2 Recruiting
100 enrolled
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Phase 1 Recruiting
12 enrolled
Epco, Zanu, Ritux for R/R FL or MZL
Phase 2 Recruiting
45 enrolled
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
Phase 3 Recruiting
375 enrolled
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Phase 1 Recruiting
27 enrolled
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
Phase 2 Recruiting
43 enrolled
Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.
Phase 2 Recruiting
23 enrolled
Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma
Phase 4 Recruiting
88 enrolled
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Phase 1 Recruiting
20 enrolled
Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
Recruiting
300 enrolled
Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
Phase 2 Recruiting
42 enrolled
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1 Recruiting
36 enrolled
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
Phase 2 Recruiting
52 enrolled
Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Phase 3 Recruiting
260 enrolled
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
Phase 2 Recruiting
30 enrolled
Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
Phase 2 Recruiting
23 enrolled
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
Phase 2 Recruiting
27 enrolled
A Cohort Study in Newly Diagnosed MZL
Recruiting
2,500 enrolled
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Phase 2 Recruiting
40 enrolled
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Recruiting
15,000 enrolled
Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 Recruiting
46 enrolled
Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
Phase 2 Recruiting
169 enrolled
Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
Phase 2 Recruiting
50 enrolled
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
Phase 2 Recruiting
65 enrolled
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Phase 1 Recruiting
148 enrolled
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Phase 1 Recruiting
37 enrolled
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Recruiting
Allo HSCT Using RIC and PTCy for Hematological Diseases
Phase 2 Recruiting
56 enrolled
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
Phase NA Recruiting
40 enrolled
Registry of Older Patients With Cancer
Recruiting
3,000 enrolled
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 Recruiting
300 enrolled
Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL: A Randomized, Open Phase II Trial
Phase 2 Recruiting
90 enrolled
Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma
Phase 2 Recruiting
51 enrolled
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
Phase 2 Recruiting
42 enrolled
ZanOs
Recruiting
59 enrolled
MarZoLyOss
Recruiting
160 enrolled
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Phase 2 Recruiting
30 enrolled
MOTIVE
Recruiting
500 enrolled
ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma
Phase NA Recruiting
83 enrolled
Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma
Phase 2 Recruiting
51 enrolled
Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy
Phase NA Recruiting
36 enrolled
Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas
Phase 2 Recruiting
45 enrolled
Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
Phase 2 Recruiting
45 enrolled
Clinical Study of OR for Second-line Treatment of Refractory MZL
Phase 4 Recruiting
39 enrolled